IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION

CourtDistrict Court, S.D. New York
DecidedApril 24, 2025
Docket1:19-cv-01578
StatusUnknown

This text of IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION (IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION, (S.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT DATE FILED: 4/24/25 SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------- X : 19-CV-1578 (VEC) IN RE: NAVIDEA BIOPHARMACEUTICALS : LITIGATION : OPINION AND ORDER : -------------------------------------------------------------- X VALERIE CAPRONI, United States District Judge: After five years of protracted litigation and incessant motion practice, this case was whittled down to a single breach of contract counterclaim against Navidea Biopharmaceuticals, Inc. (“Navidea”) by Michael Goldberg. After a three-day trial, the jury returned a verdict in Navidea’s favor. Verdict Sheet, Dkt. 408. Goldberg moved pursuant to Federal Rule of Civil Procedure 60(b)(6) and 54(b) to reinstate his quantum meruit claim, Dkt. 412, which the Court had dismissed in response to Navidea’s Motion to Dismiss more than five years ago. Dkt. 61 (“MTD Op.”). The Court construes Goldberg’s motion as one for reconsideration of that decision. For the reasons set forth below, Goldberg’s motion is DENIED. Following trial, both parties moved for attorneys’ fees pursuant to a fee-shifting provision in the August Agreement, the contract that gave rise to this dispute. Navidea Fees Mot., Dkt. 423; Goldberg Fees Mot., Dkt. 425. That provision shifts the obligation to pay the prevailing party’s attorneys’ fees to the losing party. Because neither party is the prevailing party, both motions for fees are DENIED. BACKGROUND1 This litigation began when Navidea sued Goldberg for breach of contract, among other claims. Am. Compl., Dkt. 15. Goldberg asserted multiple counterclaims, including breach of 1 The Court assumes familiarity with the underlying facts and procedural history of this case, which are set forth in detail in the Court’s multiple opinions in this case. See MTD Op., Dkt. 61; Motion for Attorneys’ Fees Opinion, Dkt. 134; Opinion Adopting Report & Recommendation, Dkt. 207; Motion for Reconsideration Opinion, contract and quantum meruit, against Navidea and its subsidiary Macrophage. Answer, Dkt. 31. Because Goldberg did not allege that the August Agreement is invalid or unenforceable, the Court dismissed his quantum meruit counterclaim; although quantum meruit can be alleged in the alternative to breach of contract, to do so requires allegations (also in the alternative) that the

contract is not enforceable. See MTD Op. at 17–18. After extensive motion practice, the Court resolved on summary judgment all of the claims other than Goldberg’s breach of contract claim against Navidea. See Summary Judgment Op. at 28. Some claims were resolved in Goldberg’s favor, id. at 12–13, 19, and another was resolved in Macrophage’s favor, see id. at 28. In advance of the final pretrial conference, having received proposed requests to charge and proposed verdict sheets from the parties, Joint Pretrial Order, Dkt. 386, the Court provided the parties with its proposed preliminary jury instructions, final jury charge, and verdict sheet. The proposed preliminary jury instructions and charge both stated that in order to prevail on his breach of contract claim, Goldberg had to prove, inter alia, that there was a valid contract between him and Navidea. Declaration of Gregory Zimmer (“Zimmer Decl.”) Ex. 1 at 4, Dkt.

414–1; id. Ex. 2 at 12, Dkt. 414–2. At the final pretrial conference, Goldberg objected to the Court’s proposed preliminary jury instructions and final jury charge, asserting that the Court had already determined that the August Agreement was a valid and binding contract when it decided Navidea’s motion to

Dkt. 261; Daubert Opinion, Dkt. 290; Summary Judgment Opinion, Dkt. 339; Motion for Reconsideration Opinion, Dkt. 351.

The Court will refer to the relevant submissions as follows: Goldberg memorandum of law in support of his motion for reconsideration, Dkt. 413, as “Goldberg Mem.”; Navidea’s memorandum of law in opposition to Goldberg’s motion for reconsideration, Dkt. 417, as “Navidea Opp.”; Goldberg’s reply in support of his motion for reconsideration, Dkt. 418, as “Goldberg Reply”; Navidea’s motion for attorney fees, Dkt. 423, as “Navidea Fees Mot.”; Goldberg’s motion for attorney fees, Dkt. 425, as “Goldberg Fees Mot.”; Navidea’s response in opposition to Goldberg’s Fees Motion, Dkt. 429, as “Navidea Fees Opp.”; and Goldberg’s response in opposition to Navidea’s Fees Motion, Dkt. 430, as “Goldberg Fees Opp.” dismiss his counterclaims. Zimmer Decl. ¶ 6. Because the Court intended to submit the question of the August Agreement’s validity to the jury, Goldberg moved for a declaration that the August Agreement between the parties was a valid and binding contract and for leave to reinstate his quantum meruit claim. Goldberg Mot., Dkt. 398. The Court denied the motion. December 17,

2024 Order, Dkt. 406. After both parties had rested, the jury was charged as follows: To prevail on his breach of contract claim, Dr. Goldberg must prove, by a preponderance of the evidence, three elements:

First, that there was a valid contract between him and Navidea; Second, that Navidea did not do what it was required to do under the contract; and Third, that Dr. Goldberg was damaged by Navidea’s breach. Jury Instructions at 11, Dkt. 409. The jury returned a verdict in favor of Navidea, finding that Goldberg did not prove his breach of contract claim. See Verdict Sheet. Goldberg, relying on Fed. R. Civ. P. 54(b) and 60(b)(6) and the Court’s inherent authority, moved to “reinstate” his quantum meruit claim. Goldberg Mot., Dkt. 412. For the reasons that follow, that motion is DENIED. Both parties moved for an award of attorneys’ fees pursuant to the fee shifting provision in the August Agreement. Those motions are also DENIED. DISCUSSION I. Legal Standard for Goldberg’s Motion to “Reinstate” his Quantum Meruit Claim

Rule 60(b)(6) is a catch-all provision that permits a district court to grant relief from a final judgment for “any . . . reason that justifies relief.” Fed. R. Civ. P. 60(b)(6). Rule 54(b) provides that “any order or other decision . . . that adjudicates fewer than all the claims or the rights and liabilities of fewer than all the parties does not end the action as to any of the claims or parties and may be revised at any time before the entry of a judgment adjudicating all the claims and all the parties’ rights and liabilities.” Fed. R. Civ. P. 54(b). As a general matter, Rule 60(b) motions are “disfavored”, Simon v. United States, No. 12- CV-5209, 2020 WL 832887, at *3 (S.D.N.Y. Feb. 20, 2020), and relief is “properly invoked

only when there are extraordinary circumstances justifying relief” or “when the judgment may work an extreme and undue hardship,” Nemaizer v. Baker, 793 F.2d 58, 63 (2d Cir. 1986) (citations omitted). See also Harris v. United States, 367 F.3d 74, 81 (2d Cir. 2004) (cleaned up) (“[A] proper case for Rule 60(b)(6) relief is only one of extraordinary circumstances, or extreme hardship.”). The burden of proof is on the party seeking relief from the judgment. Marrero Pichardo v. Ashcroft, 374 F.3d 46, 55 (2d Cir. 2004). Because Goldberg seeks to reinstate a claim that the Court already dismissed, his motion is construed as a motion for reconsideration.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Aczel v. Labonia
584 F.3d 52 (Second Circuit, 2009)
Roy William Harris v. United States
367 F.3d 74 (Second Circuit, 2004)
Analytical Surveys, Inc. v. Tonga Partners, L.P.
684 F.3d 36 (Second Circuit, 2012)
Mahani v. Edix Media Group, Inc.
935 A.2d 242 (Supreme Court of Delaware, 2007)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
Associated Press v. United States Department of Defense
395 F. Supp. 2d 17 (S.D. New York, 2005)
Sternberg v. Nanticoke Memorial Hosp., Inc.
62 A.3d 1212 (Supreme Court of Delaware, 2013)
McGraw-Hill Global Educ. Holdings, LLC v. Mathrani
293 F. Supp. 3d 394 (S.D. Illinois, 2018)
Marrero Pichardo v. Ashcroft
374 F.3d 46 (Second Circuit, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-navidea-biopharmaceuticals-litigation-nysd-2025.